Hematologic risk factors for stroke in Saudi children

Saudi Medical Journal

Volumn 27, Issue SUPPL., 2006, Pages

  Salih, Mustafa A M ^a   Abdel Gader, Abdel Galil M ^a   Al Jarallah, Ahmed A ^a   Kentab, Amal Y ^a   Alorainy, Ibrahim A ^a   Hassan, Hamdy H ^a   Bahakim, Hassan M ^a   Kurbaan, Khadija M ^a   Zahraa, Jihad N ^a   Murshid, Waleed R ^a   El Hazmi, Mohsen A ^a   Khoja, Waleed A ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b The General Directorate of Armed Forces Health Services   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY;

ARTICLE; BETA THALASSEMIA; BLOOD CLOTTING TEST; CEREBROVASCULAR ACCIDENT; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; FEMALE; HEMATOLOGIC DISEASE; HEMOPHILIA B; HUMAN; INFANT; IRON DEFICIENCY ANEMIA; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MOYAMOYA DISEASE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PROSPECTIVE STUDY; PROTEIN C DEFICIENCY; RETROSPECTIVE STUDY; REVASCULARIZATION; RISK ASSESSMENT; RISK FACTOR; SAUDI ARABIA; SICKLE CELL ANEMIA;

CEREBROVASCULAR ACCIDENT; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SAUDI ARABIA;

EID: 33645234705     PISSN: 03795284     EISSN: 03795284     Source Type: Journal    
DOI: None     Document Type: Article

References (118)

1. Hoppe C. Defining stroke - risk in children with sickle cell anaemia. Br J Haematol 2004; 128: 751-766.
2. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992; 120: 360-366.
3. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW et al Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91: 288-294.
4. El-Hazmi. Clinical and hematological diversity of sickle cell disease in Saudi children. J Trop Pediatr 1992; 38: 106-112.
5. Stockman JA, Nigro MA, Mishkin MM, Oski EA. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med 1972; 287: 846-849.
6. Adams RJ, Nichols FT, McKie V, McKie K, Milner P, Gammal TE. Cerebral infraction in sickle cell anemia: Mechanism based on CT and MRI. Neurology 1988; 38: 1012-1017.
7. Pavlakis SG, Prohovnik I, Piomelli S, DeVivo DC. Neurologic complication of sickle cell disease. Adv Pediatr 1989; 36: 247-276.
8. Dobson SR, Holden KR, Nietert PJ, Cure JK, Laver JH, Disco D et al. Moyamoya syndrome in childhood sickle cell disease: A predictive factor for recurrent cerebrovascular events. Blood 2002; 99: 3144-3150.
9. Portnoy BA, Herion JC. Neurological manifestations in sickle-cell disease, with a review of the literature and emphasis on the prevalence of hemiplegia. Ann Intern Med 1972; 76: 643-652.
10. Adeloye A, Ogbeide MI, Odeku EL. Massive intracranial hemorrhage in sickle cell anemia. Neurology 1970; 20: 1165-1170.
11. Van Hoff J, Ritchey AK, Shaywitz BA. Intracranial hemorrhage in children with sickle cell disease. Am J Dis Child 1985; 139: 1120-1123.
12. Oyesiku NM, Barrow DL, Eckman JR, Tindall SC, Colohan AR. Intracranial aneurysms in sickle-cell anemia: clinical features and pathogenesis. J Neurosurg 1991; 75: 356-363.
13. Aessopos A, Farmakis D, Loukopoulos D. Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. Blood 2002; 99: 30-35.
14. Verlhac S, Bernaudin F, Tortrat D, Brugieres P, Mage K, Caston A. Detection of cerebrovascular disease in patients with sickle cell disease using transcranial Doppler sonography: correlation with MRI, MRA and conventional angiography. Pediatr Radiol 1995; 25 (Suppl): S14-S19.
15. Adams RJ, McKie VC, Carl EM, Nichols FT, Perry R, Brock K. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol 1997; 42: 669-704.
16. Adams RJ, Brambilla DJ, Grangers S, Gallagher D, Vichinsky E, Abboud MR et al. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during STOP study. Blood 2004; 103: 3689-3694.
17. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C. Prevention of a first stroke by transfusions in children in the sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 379: 5-11.
18. Adams RJ. Stroke prevention and treatment in sickle cell disease. Arch Neurol 2001; 58: 565-568.
19. Gebreyohanns M, Adams RJ. Sickle cell disease: primary stroke prevention. CNS Spectr 2004; 9: 445-449.
20. Carvalho KS, Garg BP. Arterial strokes in children. Neurol Clin 2002; 20: 1079-1100.
21. Al-Fawaz IM. Surveillance for iron deficiency anaemia at a well-baby clinic in Riyadh, Saudi Arabia. Saudi Med J 1993; 14: 27-31.
22. Hartfield DS, Lowry NJ, Keene DL, Yager JY. Iron deficiency: a cause of stroke in infants and children. Pediatr Neurol 1997; 16: 50-53.
23. DeVeber GA, Mac Gregor D, Curtis R, Mayank S. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol 2000; 15: 316-324.
24. Schafer AI. Hyper-coagulable states: molecular genetics to clinical practice. Lancet 1994; 344: 1739-1742.
25. Devilant M, Toso M, Morales M. Childhood stroke associated with protein C or S deficiency and antiphospholipid syndrome. Pediatr Neurol 1993; 9: 67-70.
26. Brown DC, Livingston JH, Minns RA, Eden OB. Protein C and S deficiency causing childhood stroke. Scott Med J 1993; 38: 114-115.
27. Marco-Johnson MJ, Nuss R. Lupus anticoagulant in children with thrombosis. Am J Hematol 1995; 48: 240-243.
28. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci 1993; 90: 1004-1008.
29. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
30. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522.
31. Chan AK, deVeber G. Prothrombotic disorders and ischemic stroke in children. Semin Pediatr Neurol 2000; 7: 301-308.
32. Gruppo R, Degrauw A, Fogelson H, Glauser T, Balasa V, Gartside P. Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. J Pediatr 2000; 137: 714-718.
33. Liesner R, Mackie I, Cookson J, McDonald S, Chitolie A, Donohoe S et al. Prothrombotic changes in children with sickle cell disease: relationships to cerebrovascular disease and transfusion. Br J Haematol 1998; 103: 1037-1044.
34. Wang HC, Tu HC, Choi WM. Ischemic stroke in a teenage girl with primary antiphospholipid antibody syndrome. J Formos Med Assoc 2000; 99: 62-65.
35. Margaglione M, D'Andrea G, Giuliani N, Brancaccio V, De Lucia D, Grandone E et al. Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with Factor V Leiden. Arterioscler Thromb Vasc Biol 1999; 19: 1751-1756.
36. deVeber G, Roach ES, Riela AR, Wiznitzer M. Stroke in children: recognition, treatment, and future directions. Semin Pediatr Neurol 2000; 7: 309-317.
37. Ganesan V, McShane MA, Liesner R, Cookson J, Hann I, Kirkham FJ. Inherited prothrombotic states and ischaemic stroke in childhood. J Neurol Neurosurg Psychiatry 1998; 65: 508-511.
38. Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001; 32: 1793-1799.
39. Voetsch B, Damasceno BO, Camargo ECS, Massaro A, Bacheschi LA, Schaff M et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 2000; 83: 229-233.
40. Riikonen RS, Vahtera EM, Kekomaki RM. Physiological anticoagulants and activated protein C resistance in childhood stroke. Acta Paediatr 1996; 85: 242-244.
41. Koller H, Stoll G, Sitzer M, Burk M, Schottler B, Freund HJ. Deficiency of both protein C and protein S in a family with ischemic strokes in young adults. Neurology 1994; 44; 1238-1240.
42. Brenner B, Fishman A, Goldsher D, Schreibman D, Tavory S. Cerebral thrombosis in a newborn with a congenital deficiency of antithrombin III. Am J Hematol 1988; 27: 209-211.
43. Ganesan V, Kelsey H, Cookson J, Osborn A, Kirkham FJ. Activated protein C resistance in childhood stroke. Lancet 1996; 347:260.
44. Lindgren A, Lindoff C, Norrving B, Astedt B, Johansson BB. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 1996; 27: 1066-1071.
45. Schoning M, Kelin R, Krageloh-Mann I, Falck M, Bien S, Berg PA et al. Antiphospholipid antibodies in cerebrovascular ischemia and stroke in childhood. Neuropediatrics 1994; 25: 8-14.
46. Saxena R. Activated protein C (APC) resistance in young stroke patients. Thromb Haemost 1999; 81: 465-466.
47. Tardy-Poncet B, Rayet G, Damon G, Alhenc-Gelac M, Dutour N, Lavocat MP. Protein C concentrates in a neonate with a cerebral venous thrombosis due to heterozygous type 1 protein C deficiency. Thromb Haemost 2001; 85: 1118-1119.
48. Carvalho KS, Garg BP. Cerebral venous thrombosis and venous malformation in children. Neurol Clin 2002; 20: 1061-1077.
49. Nestoridi E, Buonanno FS, Jones RM, Krishnamoorthy K, Grant PE, Van Cott EM et al. Arterial ischemic stroke in childhood: the role of plasma-phase risk factors. Curr Opin Neurol 2002; 15: 133-138.
50. Ganesan V, Kirkham FJ. Recurrence after ischaemic stroke in childhood. Dev Med Child Neurol 1998; 40 (Suppl 79): 7.
51. Nowak-Gottl U, Strater R, Heinecke A, Junker R, Koch HG, Schuierer G et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999; 94: 3678-3682.
52. Carvalho KS, Bodensteiner JB, Connolly PJ, Garg BP. Cerebral venous thrombosis in children. J Child Neurol 2001; 16: 574-580.
53. deVeber G, Chan A, Monagle P, Marzinotto V, Armstrong D, Massicotte P et al. Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort study. Arch Neurol 1998; 55: 1533-1537.
54. Roddy SM, Giang DW. Antiphospholipid antibodies and stroke in an infant. Pediatrics 1991; 87: 933-935.
55. Rumi V, Angelini L, Scaioli V, D'Angelo A, Besana C. Primary antiphospholipid syndrome and neurologic events. Pediatr Neurol 1993; 9: 473-475.
56. Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosenberg N, Gitel S et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31: 1283-1288.
57. Cangoz E, Deba G, Akar N. Effect of factor VIIIc levels in pediatric stroke patients. Pediatr Hematol Oncol 2004; 21: 255-260.
58. Sebire G, Tabaraki B, Saunders DE, Leroy I, Liesner R, Saint-Martin C et al. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain 2005; 128: 477-489.
59. Duran R, Biner B, Demir M, Celtick C, Karasalihoglu S. Factor V Leiden mutation and other thrombophilia markers in childhood ischemic stroke. Clin Appl Thromb Hemost 2005; 11: 83-88.
60. Fakeeh KN, Al-Rasheed SA. Cerebral venous thrombosis in the nephrotic syndrome. Saudi J Kidney Dis Transplant 2000; 11: 59-63.
61. Gouault-Heilmann M, Quetin P, Dreyfus M, Gandrille S, Emmerich J, Leroy-Matheron C et al. Massive thrombosis of venous cerebral sinuses in a 2-year-old boy with a combined inherited deficiency of antithrombin III and protein C. Thromb Haemost 1994; 72: 782-783.
62. Pohl M, Zimmerhackl LB, Heinen F, Sutor AH, Schneppenheim R, Brandis M. Bilateral renal vein thrombosis and venous sinus thrombosis in a neonate with factor V mutation (FV Leiden). J Pediatr 1998; 132: 159-161.
63. Aschka I, Aumann V, Bergmann F, Budde U, Eberl W, Eckhof-Donovan S et al. Prevalence of factor V Leiden in children with thrombo-embolism. Eur J Pediatr 1996; 155: 1009-1014.
64. Hess DC, Krauss J, Adams RJ, Nichols FT, Zhang D, Rountree HA. Anticardiotipin antibodies: A study of frequency in TIA and stroke. Neurology 1991; 41: 525-528.
65. Levine SR, Welch KMA. The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies. Arch Neurol 1987; 44: 876-983.
66. Kitagawa Y, Gotoh F, Koto A, Okayasu H. Stroke in systemic lupus erythematosus. Stroke 1990; 21; 1533-1539.
67. Hart RG, Miller VT, Coull MB. Cerebral infarction associated with lupus anticoagulants: preliminary report. Stroke 1984; 15: 114-118.
68. Kelly RE, Berger JR. Ischemic stroke in a girl with lupus anticoagulant. Pediatr Neurol 1987; 3: 58-61.
69. Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980; 92: 156-159.
70. Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GR. Thrombosis in systemic lupus erythematosis: striking association with the presence of circulating lupus anticoagulant. Br Med J 1983; 287: 1021-1023.
71. Olson JC, Konkol RJ, Gill JC, Dobyns WB, Coull BM, McColl MD et al. Childhood stroke and lupus anticoagulant. Pediatr Neurol 1994; 10: 54-57.
72. McColl MD, Chalmers EA, Thomas A, Sproul A, Healey C, Rafferty I et al. Factor V Leiden, prothrombin 20210G A, and the MTHFR C677T mutations in childhood stroke. Thromb Haemost 1999; 81: 690-694.
73. Levine SR, Brey RL. Neurological aspects of antiphospholipid antibody syndrome. Lupus 1996; 5: 347-353.
74. Salih MA, Abdel-Gader AM, Al-Jarallah AA, Kentab AY, Alorainy IA, Hassan HH et al. Stroke in Saudi children. Epidemiology, clinical features and risk factors. Saudi Med J 2006; Vol. 27 Supplement 1: S12-S20.
75. Ellis BC, Stransky AA. A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 1961; 58: 477-488.
76. Ganesan V, Prengler M, McShane MA, Wade A, Kirleman FJ. Investigation of risk factors in children with arterial ischemic stroke. Ann Neurol 2003; 53: 167-173.
77. Lanthier S, Kirkham FJ, Mitchell LG, Laxer RM, Atenafu E, Male C et al. Increased anticardiolipin antibody 1gG titres do not predict recurrent stroke or TIA in children. Neurology 2004; 62: 194-200.
78. Daif A, Awada A, al-Rajeh S, Abduljabbar M, al Tahan AR, Obeid T et al. Cerebral venous thrombosis in adults. Stroke 1995; 26: 1193-1195.
79. Al-Jaouni SK. Primary thrombophilia in Saudi Arabia. Saudi Med J 2003; 24: 614-616.
80. Salama H, Rejjal A, Kattan A, Al-Mahmoud L. Neonatal cerebral infarction presenting with limb ischemia. Neurosciences 2003; 8: 191-194.
81. DeVeber G. Arterial ischemic strokes in infants and children: An overview of current approaches. Semin Thromb Hemost 2003; 29: 567-573.
82. Strater R, Becker S, Von Eckardstein A, Heinecke A, Gutsche S, Junker R et al. Prospective assessment of risk factors for recurrent stroke during childhood. A 5-year-follow-up study. Lancet 2002; 360: 1540-1545.
83. Bick RL, Pegram M. Syndromes of hypercoagulability and thrombosis: a review. Semin Thromb Hemost 1994; 20: 109-132.
84. el-Hazmi MA, Warsy AS. The pattern for common anaemia among Saudi children. J Trop Pediatr 1999; 45: 221-225.
85. Ohene-Frempong K. Stroke in sickle cell disease. Demographic, clinical, and therapeutic considerations. Sem Hematol 1991; 28: 213-219.
86. Pegelow CH, Macklin EA, Moser FG, Wang WC, Bello JA, Miller ST et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood 2002; 99: 3014-3018.
87. Awada S, Al-Rajeh S, Ammar A, Adeyokunnu A. Stroke in children: a study of 21 cases from Saudi Arabia. Ann Trop Paediatr 1994; 14: 131-135.
88. Al-Sulaiman A, Bademosi O, Ismail H, Magboll G. Stroke in Saudi Children. J Child Neurol 1999; 14: 295-298.
89. Nagel RL. Sickle cell anemia is a multigene disorder. Sickle painful crises, a case in point. Am J Hematol 1993; 42: 96-101.
90. Babiker MA, Taha SA. Two different patterns of sickle-cell disease in children in Saudi Arabia. Ann Trop Paediatr 1982; 2: 179-181.
91. El-Hazmi MA, Warsy AS. Appraisal of sickle-cell and thalassaemia genes in Saudi Arabia. East Mediterr Health J 1999; 5: 1147-1153.
92. Adekile AD, Haider MZ. Morbidity, beta S haplotype and alpha-globin gene patterns among sickle cell anemia patients in Kuwait. Acta Haematol 1996; 96: 150-154.
93. Hsu LL, Miller ST, Wright E, Kutlar A, McKie V, Klim KS et al. Alpha thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol 2003; 25: 622-628.
94. el-Hazmi MA. XmnI polymorphism in the gamma-globin gene region among Saudis. Hum Hered 1989; 39: 12-19.
95. el-Hazmi MA, Warsy AS. Molecular studies on Yemeni sickle-cell-disease patients: XmnI polymorphism. East Mediterr Health J 1999; 5: 1183-1187.
96. Kinney TR, Sleeper LA, Wang WC, Zimmerman RA, Pegelow CH, Ohene-Frempong K et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics 1999; 103: 640-645.
97. Neonato MG, Guilloud-Bataille M, Beauvais P, Begue P, Belloy M et al. Acute clinical events in 299 homozygous sickle cell patients living in France. French Study Group on Sickle Cell disease. Eur J Hematol 2000; 65: 155-164.
98. Powers DR. Beta S-gene-cluster haplotypes in sickle cell anemia. Clinical and hematologic features. Hematol Oncol Clin North Am 1991; 5: 475-493.
99. Adams GT, Snieder H, McKie VC, Clair B, Brambilla D, Adams RJ et al. Genetic risk factors for cerebrovascular disease in children with sickle cell disease: design of a case-control association study and genome wide screen. BMC Med Genet 2003; 4: 6.
100. Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA. Sickle cell anemia with moyamoya disease: outcomes after EDASA procedure. Pediatr Neurol 2003; 29: 124-130.
101. Williams J, Goff JR, Anderson HR Jr, Langston JW, Thompson E. Efficacy of transfusion therapy for one to two years in patients with sickle cell diseases and cerebrovascular accidents. J Pediatr 1980; 96: 205-208.
102. Wang WC, Kovnar EH, Tonkin IL, Mulhern RK, Langston JW, Day SW et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr 1991; 118: 377-382.
103. Ware RE, Zimmerman SA, Schultz WH. Hydroyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999; 94: 3022-3026.
104. Al-Saeed HH, Al-Salem AH. Principles of blood transfusion in sickle cell anemia. Saudi Med J 2002; 23: 1443-1448.
105. Sumoza A, de Bisotti R, Sumoza D, Fairbanks V. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol 2002; 71: 161-165.
106. Pegelow CH, Wang W, Granger S, Hsu LL, Vichinsky E, Moser FG et al. Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Arch Neurol 2001; 58: 2017-2021.
107. Abboud MR, Cure I, Granger S, Gallagher D, Hsu L, Wang W et al. Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study. Blood 2004; 103: 2822-2826.
108. Driscoll MC, Hurlet A, Styles L, McKie V, Files B, Olivieri N et al. Stroke in siblings with sickle cell anemia. Blood 2003; 101: 2401-2404.
109. Kiwiatkowski JL, Hunter JV, Smith-Whitley K, Katz ML, Shults J, Ohene-Frempong K et al. Transcranial Doppler ultrasonography in siblings with sickle cell disease. Br J Haematol 2003; 121: 932-937.
110. Al Rajeh S, Bademosi O, Ismail H, al Freihi H, Larbi E, Ibrahim AW. A community survey of neurological disorders in Saudi Arabia: The Thugbah study. Neuroepidemiology 1993; 12: 164-178.
111. Salih MAM, Mahdi A, Al Rikabi AC, Al-Bunyan M, Roberds SL, Anderson RD et al. Clinical and molecular pathological features of childhood autosomal recessive muscular dystrophy in Saudi Arabia. Dev Med Child Neurol 1996; 38: 262-270.
112. Salih MAM. Neuromuscular disorders among Arabs. In: Teebi AS, Farag TI, editors. Genetic disorders among Arab populations. Oxford: Oxford University Press; 1997. p. 126-157.
113. Fixler J, Vichinsky E, Walters MC. Stem cell transplantation for sickle cell disease: Can we reduces the toxicity? Pediatr Pathol Mol Med 2001; 20: 73-86.
114. Adams RJ, Pavlakis S, Roach ES. Sickle cell disease and stroke: primary prevention and transcranial Doppler. Ann Neurol 2003; 54: 559-563.
115. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005; 37: 435-440.
116. Al-Fawaz IM, Gader AMA, Bahakim. HM, Al-Mohareb F, Al-Momen AK, Harakati MS. Hereditary bleeding disorders in Riyadh, Saudi Arabia. Ann Saudi Med 1996; 16: 257-261.
117. Islam SI, Quadri MI. Spectrum of hereditary coagulation factor deficiencies in eastern province, Saudi Arabia. East Mediterr Health J 1999; 5: 118-195.
118. Salih MA, Abdel-Gader AM, Al-Jarallah AA. Study project on stroke in Saudi children. Conclusions, recommendations and acknowledgments. Saudi Med J 2006; Vol. 27 Supplement 1: S108-S110.